Riehl retires as CEO of Stellar Pharmaceuticals

Peter Riehl has retired as CEO, president and a director of Stellar Pharmaceuticals (OTCBB: SLXCF), effective yesterday. Arnold Tenney, who has been chairman of Stellar since 2005, will serve as the interim CEO until a permanent replacement for Mr. Riehl is retained. Stellar markets direct in Canada and in countries around the world through out-licensing [...]

Stellar in non-brokered private placement

Stellar Pharmaceuticals (OTCBB: SLXCF) is arranging a non-brokered private placement, consisting of up to one million units at a price of $1 (U.S.) a unit. Each unit will consist of one common share and one-half of a Series 1 warrant, one-half of a Series 2 warrant and one-half of a Series 3 warrant. During the [...]

Stellar signs Uracyst distributor in Spain

Stellar Pharmaceuticals (OTCBB: SLXCF) has signed a license agreement with Laboratorios Inibsa S.A. for the sale and distribution in Spain of one of its lead products, Uracyst, for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst already has CE mark approval in Europe and Inibsa is expected to launch the drug in the fourth quarter [...]

Stellar gets Uracyst patents in China and U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has been issued patents for Uracyst, one of its lead products for the treatment of interstitial cystitis/painful bladder syndrome, by both the Chinese Patent Office and the U.S. Patent and Trademark Office. The Chinese patent covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the [...]